

**From:** CBER Complicheck  
**Sent:** Friday, June 03, 2011 2:38 PM  
**To:** Peters, Lori  
**Subject:** RE: Request for Compliance Check -----(b)(4)----- under BLA 125384/0, Action Due 6/3/11

Firm:  
Applicant: Kedrion, S.p.A.  
Address: Loc. Ai Conti, 55051 Castelvecchio Pascoli, Barga (Lucca), Italy (Headquarters address, production address is listed below.)  
US License Number (if any): Not official  
FEI#: 3008919567

Kedrion Biopharmaceutical, S.p.A  
Via Provinciale  
Bolognana, Gallicano (Lucca)  
Italy 55027  
FEI# 3008919567

-----~~(b)(4)~~-----  
-----~~(b)(4)~~-----  
-----~~(b)(4)~~-----  
-----~~(b)(4)~~-----

STN #: BLA 125384/0

Summary: Kedrion Biopharmaceuticals, S.p.A. is seeking licensure for their 25% Human Albumin Solution (intravenous). This will be Kedrion's first licensed product sold in the US. Kedrion was inspected by DMPQ and OBRR in February 2011 and it was the first ever inspection of the facility. Kedrion purchases the albumin paste, an intermediate in the production of the final product, -----(b)(4)-----.

A Pre-approval inspection (PAI) of Kedrion Biopharmaceuticals, S.p.A. was conducted February 23-25, 28 and March 1-2, 2011 and classified as Voluntary Action Indicated (VAI). The inspection was endorsed on May 31, 2011 and final closeout memo is dated May 31, 2011. Therefore, the Office of Compliance and Biologics Quality, Division of Case Management does not object to the approval of this supplement. Therefore, the Office of Compliance and Biologics Quality, Division of Case Management does not object to the approval of this supplement.

Shannon Aldrich, CSO  
CBER/OCBQ/DCM/HFM-610

---

**From:** Peters, Lori  
**Sent:** Friday, June 03, 2011 11:53 AM  
**To:** CBER Complicheck  
**Cc:** Renshaw, Carolyn; Trout, Deborah; Norwood, Laurie; Eltermann, John; McGuire, Jeffrey

**Subject:** Request for Compliance Check -----(b)(4)----- under BLA 125384/0, Action Due 6/3/11

Hello -  
DMPQ is requesting a second compliance check for BLA STN 125384/0 -  
----- (b)(4) ----- of the albumin paste  
intermediate to Kedrion. Kedrion is seeking licensure and approval for  
the manufacture of the albumin paste into the final product of the 25%  
Human Albumin Solution.

**ESTABLISHMENT EVALUATION REQUEST**

Date: June 3, 2011  
Request Type: Original  
Reviewer's Name, Division, Mail Code, Phone#:  
Lori Peters, DMPQ, HFM-676, 301-827-1338  
Application Number or Supplement Number and Type:  
BLA; 125384/0  
Due Date: June 3, 2011

Brief Description of the application or detailed summary of the  
supplement, including product's and establishment's (Indicate if the  
supplement represents an improvement or change intended to help the  
applicant or location achieve compliance):

Kedrion Biopharmaceuticals, S.p.A. is seeking licensure for their 25%  
Human Albumin Solution (intravenous). This will be Kedrion's first  
licensed product sold in the US. Kedrion was inspected by DMPQ and  
OBRR in February 2011 and it was the first ever inspection of the  
facility. Kedrion purchases the albumin paste, an intermediate in the  
production of the final product, -----(b)(4)-----.

Applicant: Kedrion, S.p.A.  
Address: Loc. Ai Conti, 55051 Castelvecchio Pascoli, Barga (Lucca), Italy  
(Headquarters address, production address is listed below.)  
US License Number (if any): Not official  
FEI#: 3008919567

The address of the manufacturing facility where the Albumin is  
manufactured is the following: Via Provinciale; Bolognana, Galliciano  
(Lucca); Italy 55027

----- (b)(4) -----  
----- (b)(4) -----  
----- (b)(4) -----  
----- (b)(4) -----

**Lori Peters**

**Consumer Safety Officer  
FDA/CBER/OCBQ/DMPQ  
5516 Nicholson Lane  
Bldg A, Room 251  
Kensington MD 20895  
Office 301-827-1338  
Fax 301-827-3536**